192 related articles for article (PubMed ID: 23728220)
1. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
[TBL] [Abstract][Full Text] [Related]
2. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Maurer GD; Tritschler I; Adams B; Tabatabai G; Wick W; Stupp R; Weller M
Neuro Oncol; 2009 Dec; 11(6):747-56. PubMed ID: 19221171
[TBL] [Abstract][Full Text] [Related]
3. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
Mikkelsen T; Brodie C; Finniss S; Berens ME; Rennert JL; Nelson K; Lemke N; Brown SL; Hahn D; Neuteboom B; Goodman SL
Int J Cancer; 2009 Jun; 124(11):2719-27. PubMed ID: 19199360
[TBL] [Abstract][Full Text] [Related]
4. Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.
Cheng NC; van Zandwijk N; Reid G
PLoS One; 2014; 9(3):e90374. PubMed ID: 24595274
[TBL] [Abstract][Full Text] [Related]
5. Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.
Gvozdenovic A; Boro A; Meier D; Bode-Lesniewska B; Born W; Muff R; Fuchs B
Oncotarget; 2016 Aug; 7(34):55141-55154. PubMed ID: 27409827
[TBL] [Abstract][Full Text] [Related]
6. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.
Albert JM; Cao C; Geng L; Leavitt L; Hallahan DE; Lu B
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1536-43. PubMed ID: 16863930
[TBL] [Abstract][Full Text] [Related]
7. In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines.
Lautenschlaeger T; Perry J; Peereboom D; Li B; Ibrahim A; Huebner A; Meng W; White J; Chakravarti A
Radiat Oncol; 2013 Oct; 8():246. PubMed ID: 24153102
[TBL] [Abstract][Full Text] [Related]
8. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.
Alghisi GC; Ponsonnet L; Rüegg C
PLoS One; 2009; 4(2):e4449. PubMed ID: 19212436
[TBL] [Abstract][Full Text] [Related]
9. Cell surface overexpression of alphavbeta5 integrin impedes alphavbeta3-mediated migration of the human ovarian adenocarcinoma cell line IGROV1.
Maubant S; Leroy-Dudal J; Carreiras F; Deslandes E; Duigou F; Staedel C; Gauduchon P
Cell Biol Int; 2007 Feb; 31(2):109-18. PubMed ID: 17074516
[TBL] [Abstract][Full Text] [Related]
10. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.
Monferran S; Skuli N; Delmas C; Favre G; Bonnet J; Cohen-Jonathan-Moyal E; Toulas C
Int J Cancer; 2008 Jul; 123(2):357-364. PubMed ID: 18464290
[TBL] [Abstract][Full Text] [Related]
11. The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
Wilisch-Neumann A; Kliese N; Pachow D; Schneider T; Warnke JP; Braunsdorf WE; Böhmer FD; Hass P; Pasemann D; Helbing C; Kirches E; Mawrin C
Clin Cancer Res; 2013 Oct; 19(19):5402-12. PubMed ID: 23948974
[TBL] [Abstract][Full Text] [Related]
12. A small-molecule RGD-integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells.
Russo MA; Paolillo M; Sanchez-Hernandez Y; Curti D; Ciusani E; Serra M; Colombo L; Schinelli S
Int J Oncol; 2013 Jan; 42(1):83-92. PubMed ID: 23174862
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
Beekman KW; Colevas AD; Cooney K; Dipaola R; Dunn RL; Gross M; Keller ET; Pienta KJ; Ryan CJ; Smith D; Hussain M
Clin Genitourin Cancer; 2006 Mar; 4(4):299-302. PubMed ID: 16729916
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of the coxsackie and adenovirus receptor downregulates αvβ3 and αvβ5 integrin expression and reduces cell adhesion and migration.
Majhen D; Stojanović N; Špeljko T; Brozovic A; De Zan T; Osmak M; Ambriović-Ristov A
Life Sci; 2011 Aug; 89(7-8):241-9. PubMed ID: 21712047
[TBL] [Abstract][Full Text] [Related]
15. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.
Oliveira-Ferrer L; Hauschild J; Fiedler W; Bokemeyer C; Nippgen J; Celik I; Schuch G
J Exp Clin Cancer Res; 2008 Dec; 27(1):86. PubMed ID: 19114005
[TBL] [Abstract][Full Text] [Related]
16. Small molecule integrin antagonists in cancer therapy.
Paolillo M; Russo MA; Serra M; Colombo L; Schinelli S
Mini Rev Med Chem; 2009 Oct; 9(12):1439-46. PubMed ID: 19929817
[TBL] [Abstract][Full Text] [Related]
17. [Tumor cell-tumor endothelial cell adhesion mediated by alphavbeta3 and alphavbeta5 molecules].
Niu JX; Zhang WJ; Ye LY; Wu LQ; Yang ZH; Zhu GJ; Lou JN
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):165-9. PubMed ID: 18756928
[TBL] [Abstract][Full Text] [Related]
18. Microglial expression of alphavbeta3 and alphavbeta5 integrins is regulated by cytokines and the extracellular matrix: beta5 integrin null microglia show no defects in adhesion or MMP-9 expression on vitronectin.
Milner R
Glia; 2009 May; 57(7):714-23. PubMed ID: 18985734
[TBL] [Abstract][Full Text] [Related]
19. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
[TBL] [Abstract][Full Text] [Related]
20. Zoledronate inhibits alphavbeta3 and alphavbeta5 integrin cell surface expression in endothelial cells.
Bellahcène A; Chaplet M; Bonjean K; Castronovo V
Endothelium; 2007; 14(2):123-30. PubMed ID: 17497369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
